Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. (RMD) is a health technology company focused on sleep, breathing, and care delivered in the home, and its news flow reflects that focus. Company announcements regularly describe how ResMed creates life-changing health technologies, combining AI-powered digital health solutions, cloud-connected devices, and intelligent software to support sleep and breathing therapy for people in more than 140 countries.
Investors following RMD news can expect updates on financial performance and capital returns, including quarterly earnings releases, dividend declarations, and details of investor webcasts. ResMed frequently issues press releases about its results of operations, margins, cash flow, and related board decisions such as quarterly cash dividends, as documented in its Form 8-K filings and Globe Newswire announcements.
ResMed’s news also highlights product and technology developments. Recent communications include FDA clearance for Smart Comfort, an AI-enabled digital medical device that recommends personalized comfort settings for CPAP therapy, and design awards for the AirTouch N30i nasal cradle mask. These stories often emphasize the use of real-world sleep data, machine learning, and human-centered design to improve comfort and adherence for people with obstructive sleep apnea.
Another recurring theme in ResMed’s news is research and clinical insights. The company has announced landmark studies in The Lancet Respiratory Medicine projecting future obstructive sleep apnea prevalence, as well as meta-analyses on CPAP therapy and mortality. It has also launched initiatives like Sleep Institute to publish evidence-based insights that inform care models and policy discussions around sleep health.
Corporate governance and investor-relations events appear frequently in RMD news as well, including participation in major healthcare conferences, updates on board composition, and details of annual meetings. For readers and investors, the RMD news page offers a centralized view of ResMed’s earnings, product clearances, research publications, and strategic initiatives related to sleep and breathing health.
ResMed has acquired MEDIFOX DAN, a leading German software solutions provider, for €958.6 million ($997.5 million). This strategic acquisition marks ResMed's first expansion of its SaaS business into Germany, the second largest healthcare market globally. MEDIFOX DAN will enhance ResMed's portfolio with outpatient therapy service offerings, and its operations will integrate within ResMed's SaaS segment. The acquisition is expected to be accretive to non-GAAP diluted earnings per share, while ResMed plans to retain all MEDIFOX DAN employees and maintain its current brand.
ResMed (NYSE: RMD) reported a 5% year-over-year revenue growth for Q1 2023, totaling $950.3 million, with a 9% increase on a constant currency basis. Operating profit rose 5%, while non-GAAP operating profit increased 4%. Diluted earnings per share increased to $1.43, with a non-GAAP EPS of $1.51. The company noted strong sales in the Americas and expanding gross margins despite increased SG&A expenses. Additionally, ResMed announced the acquisition of mementor and unveiled plans to double its R&D workforce in Ireland.
ResMed (NYSE: RMD) will release its financial and operational results for Q1 FY 2023 on October 27, 2022, post-market hours. A webcast will follow to discuss these results and any additional forward-looking information. The earnings call will be accessible to international audiences, with a replay available shortly after. ResMed focuses on innovative healthcare solutions that enhance the quality of life for individuals with chronic diseases, aiming to lower costs for consumers and healthcare systems globally.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will participate in a fireside chat at the Bank of America Global Healthcare Conference on September 14, 2022, at 9:05 a.m. BST in London. This event will be accessible via a live webcast, with a replay available approximately three hours after the event until December 13, 2022. ResMed continues to innovate with digital health technologies and cloud-connected medical devices, aiming to enhance the quality of life for patients suffering from chronic diseases globally.
ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a fireside chat at the 20th Annual Morgan Stanley Global Healthcare Conference on September 12, 2022, at 8:45 a.m. ET in New York City. The event will include a live webcast, with a replay available three hours after it concludes, accessible until March 11, 2023. ResMed focuses on innovative solutions for chronic diseases, aiming to improve quality of life and reduce healthcare costs globally.
ResMed's latest research reveals that over 480 million people globally suffer from chronic obstructive pulmonary disease (COPD), a prevalence significantly higher—by 22–126%—than previous estimates. This figure could escalate to 592 million by 2050 if current trends in smoking and air pollution continue. COPD costs the EU approximately €48.4 billion annually, with the U.S. facing over $3 billion in hospitalization costs alone. The study urges immediate action for better screening and treatment, stressing the importance of reducing risk factors associated with COPD.
ResMed reported a 4% increase in year-over-year revenue for Q4 2022, totaling $914.7 million. Operating profit rose 6%, with diluted earnings per share at $1.33. Annual revenue reached $3.6 billion, marking a 12% growth. Despite a 90 bps contraction in gross margin to 56.6%, non-GAAP measures showed resilience with an operating profit increase of 8% for the year. The board declared a 5% increase in dividends to $0.44 per share. The company is optimistic about growth in FY23, aided by new product launches and an upcoming acquisition of MEDIFOX DAN for $1 billion.
ResMed has acquired Leipzig-based mementor as of August 1, 2022, enhancing its digital sleep medicine portfolio in Germany. This strategic move integrates mementor’s somnio, a digital insomnia therapy solution, into ResMed's offerings, filling a significant care gap for patients suffering from insomnia. Somnio, which is the only permanently approved Digital Health Application (DiGA) for insomnia in Germany, is now available via prescription and eligible for reimbursement. This acquisition aims to expand access to effective sleep treatments and leverage ResMed's network for greater adoption.
ResMed (NYSE: RMD) has announced it will release its fourth-quarter fiscal year 2022 financial results on August 11, 2022, after the NYSE closes. Following this, management will host a webcast to discuss the outcomes and other material information. The webcast will be accessible at http://investor.resmed.com. A replay will be available shortly post-webcast, including a phone replay accessible until August 25. ResMed continues to focus on innovative solutions for chronic disease management, aiming to improve quality of life and reduce healthcare costs.
ResMed has announced the promotion of Lucile Blaise to President of Sleep & Respiratory Care, effective July 1, 2022. Blaise, with over 25 years in the medtech industry, previously served as Vice President for Western Europe. She has been influential in establishing payer market access for digital health in France and Belgium and advocates for data privacy and real-world evidence in healthcare. CEO Mick Farrell praised her commitment to patient-centric care and innovative leadership, highlighting her vital role in improving treatments for chronic diseases.